The company also has a THC product in the pipeline that Anido hopes will find applications for Tourette’s syndrome. “We’ve done some Phase 1 trials, but we haven’t gotten it to the right blood levels," Anido said. “So for the moment it has been back-burnered. We’ll come back to it when we figure it out.”